Mankind Pharma (NSE:MANKIND) Change In Receivables : ₹0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mankind Pharma Change In Receivables?

Mankind Pharma's change in receivables for the quarter that ended in Mar. 2024 was ₹0 Mil. It means Mankind Pharma's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Mankind Pharma's change in receivables for the fiscal year that ended in Mar. 2024 was ₹-2,899 Mil. It means Mankind Pharma's Accounts Receivable increased by ₹2,899 Mil from Mar. 2023 to Mar. 2024 .

Mankind Pharma's Accounts Receivable for the quarter that ended in Mar. 2024 was ₹8,483 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Mankind Pharma's Days Sales Outstanding for the three months ended in Mar. 2024 was 31.71.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Mankind Pharma's liquidation value for the three months ended in Mar. 2024 was ₹24,947 Mil.

Mankind Pharma Change In Receivables Historical Data

The historical data trend for Mankind Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mankind Pharma Change In Receivables Chart

Mankind Pharma Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Change In Receivables

-3,132.53

2,002.30

-659.53

-2,053.15

-2,899.10

Mankind Pharma Quarterly Data
	Mar20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial							-	-	-	-	-

Mankind Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

Mankind Pharma (NSE:MANKIND) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Mankind Pharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	8482.812	/	24410.992	*	91
=	31.71

2. In Ben Graham's calculation of liquidation value, Mankind Pharma's accounts receivable are only considered to be worth 75% of book value:

Mankind Pharma's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	34692.43	-	23874.666	+	0.75 * 8482.812	+	0.5 * 15534.612
=	24,947

Mankind Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Mankind Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Mankind Pharma (NSE:MANKIND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mankind Pharma Ltd (NSE:MANKIND) » Definitions » Change In Receivables

Traded in Other Exchanges

543904:India

Address

262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020

Website

https://www.mankindpharma.com

Mankind Pharma Ltd is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News and Gas-O-Fast.

Mankind Pharma (NSE:MANKIND) Headlines

No Headlines